Clinical trial 2013

This study will be recruiting shortly, and is open to qualifying Type 1 Infants. Canadian location is Toronto Hospital for Sick Children. From Cure SMA-US: ISIS Pharmaceuticals Initiates Clinical Study in Infants with Spinal Muscular Atrophy. (April 23, 2013) Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced the initiation of a Phase 2 study of ISIS-SMNRx in…

Canadian SMA Research News

Canadian SMA Research News2012 Cure SMA Canada is proud to have offered major support to the Canadian Neuromuscular Disease Registry in support of SMA registration. This registration will make a substantial impact on standardizing care for SMA across Canada. It will also help initiate the offer of clinical trials in Canada as well as supplying…

$140,000 Grant to Jocelyn Côté, PhD

Cure SMA Canada Awards $140,000 Grant to Joceyln Côté, PhD, University of Ottawa Cure SMA Canada has awarded a $140,000 research grant to Joceyln Côté, PhD, at The University of Ottawa, for his project, “Investigating the mechanism by which SMN regulates translation: identification of novel therapeutic targets.” Understanding the function of the SMN protein is…

First ever therapy for SMA

Spinraza became the first ever approved treatment for SMA in the USA in December 2016. Spinraza became the first ever approved treatment for SMA in the USA in December 2016. Spinraza became the first ever approved treatment for SMA in the USA in December 2016. Spinraza became the first ever approved treatment for SMA in the USA…